1996
Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy
Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T‐cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996, 77: 1912-1917. PMID: 8646693, DOI: 10.1002/(sici)1097-0142(19960501)77:9<1912::aid-cncr23>3.0.co;2-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBody Surface AreaChemotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRadiotherapy DosageRadiotherapy, High-EnergyRemission InductionRetrospective StudiesSkinSkin NeoplasmsSurvival RateConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaComplete clinical responseOverall survivalSkin involvementT-cell lymphomaMedian DFSPrognostic indicatorTotal skin electron beam radiation therapyToxicity of therapyElectron beam radiation therapyBeam radiation therapyTotal skin surfaceElectron beam therapyFree survivalClinical responsePrognostic significanceTumor nodulesRadiation therapyPatientsPatient recordsTherapyDiseaseBeam therapyMonths
1994
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapyThe utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT]
Kolenli S, Kacinski B, Quiros P, Wilson L, Heald P, Edelson R, Braverman I. The utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 266. DOI: 10.1016/0360-3016(94)90820-6.Peer-Reviewed Original Research